US FDA approves Lilly and Incyte’s Olumiant for treating certain hospitalised patients with COVID-19
Olumiant is the first and only FDA-approved JAK inhibitor for the treatment of COVID-19 in certain hospitalised adults requiring various degrees of oxygen support
Eli Lilly and Company and Incyte announced recently that the US Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for the treatment of COVID-19 in hospitalised adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4 mg once daily for 14 days or until hospital discharge, whichever comes first, a company statement said.
The FDA’s approval is supported by results from two randomised, double-blind, placebo-controlled phase-III studies (ACTT-2 and COV-BARRIER, including the COV-BARRIER OS 7 adde